Q-omics provides the consensus-scored RPL7P41 profile across patient tissues and cancer cell-line models. RPL7P41 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPL7P41 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, RPL7P41 RNA expression shows 6,306 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, THCA, and STAD as cancer lineages where RPL7P41 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7P41 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7P41 survival associations across molecular data types. RPL7P41 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7P41 RNA expression–survival associations across cancer types. High RPL7P41 expression shows unfavorable associations in UVM, OV, MESO, KICH and BRCA, but favorable associations in HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UVM as the clearest survival context for RPL7P41 RNA expression.
This table summarizes RPL7P41 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7P41. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7P41 shows lower tumor expression in THCA and LUSC and higher tumor expression in COAD, HNSC and KICH. The THCA box plot shows higher RPL7P41 RNA expression in normal versus tumor tissue (log2 FC = −0.264, t-test p < 0.001).
This table shows molecular features associated with RPL7P41 in patient tissues and cancer cell lines. In patient samples, RPL7P41 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
